How to Get Prolia (Denosumab) in New Hampshire

What Is Prolia (Denosumab) and Why It Is Used

Prolia is a fully human monoclonal antibody that binds RANK Ligand (RANKL), blocking osteoclast formation and reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high risk of fracture, and the label was later expanded to include men with osteoporosis and patients on glucocorticoid therapy [1].

The FREEDOM trial (N=7,868) showed denosumab 60 mg every 6 months reduced new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26 to 0.41, P<0.001) and hip fractures by 40% (relative risk 0.60 to 95% CI 0.37 to 0.97) over 36 months compared with placebo [2]. Those numbers make it one of the most effective antiresorptive agents in modern osteoporosis care.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines state: "Denosumab is recommended as first-line pharmacologic therapy for patients with osteoporosis who are at very high risk of fracture, particularly those with renal impairment where bisphosphonates may be contraindicated" [3]. For New Hampshire patients who have failed bisphosphonate therapy, experienced GI intolerance, or carry a creatinine clearance below 35 mL/min, denosumab is often the clinically appropriate next step.

A single 60 mg subcutaneous injection is administered by a clinician or trained nurse every 6 months. Patients do not self-inject; the shot is delivered in a medical office, infusion center, or, in some NH counties, a mobile health clinic.

Step 1: Get an Osteoporosis Diagnosis and Bone Density Scan

Before any prescriber in New Hampshire can legally write for Prolia, a formal diagnosis must exist. The standard diagnostic tool is dual-energy X-ray absorptiometry (DXA). A T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip meets the World Health Organization definition of osteoporosis [4]. Patients with a T-score between -1.0 and -2.5 (osteopenia) may also qualify if a FRAX 10-year major osteoporotic fracture probability exceeds 20% or hip fracture probability exceeds 3%, per the National Osteoporosis Foundation threshold used widely across NH practices.

DXA scans are available at major NH hospitals including Dartmouth Health (Lebanon), Catholic Medical Center (Manchester), and Concord Hospital. Most NH Medicare Advantage plans cover a DXA scan every 24 months for eligible women age 65 and older. Bring the printed DXA report to your prescriber appointment or upload it through a telehealth portal, because no insurer or PA reviewer will process a Prolia authorization without it.

Step 2: Required Lab Work Before the First Injection

Specific labs must be drawn before the first Prolia dose and checked periodically thereafter. Hypocalcemia is the most clinically significant risk, occurring in roughly 2% of patients in the FREEDOM extension cohort [5]. Prescribers in New Hampshire uniformly require these baseline values:

• Serum calcium (corrected for albumin). Must be within normal range before injection.
• 25-hydroxyvitamin D. A level below 20 ng/mL should be corrected with supplementation before starting.
• Serum creatinine and eGFR. Severe renal impairment (eGFR <30 mL/min) increases hypocalcemia risk and requires closer monitoring, though denosumab is not renally cleared and is not dose-adjusted.
• Serum phosphorus. Ordered less consistently but may be requested by endocrinologists managing complex metabolic bone disease.

Most NH Quest Diagnostics and LabCorp locations can process these panels within 24 to 72 hours. Telehealth providers can order lab work digitally; patients get a requisition by email and choose a local draw site. Calcium supplementation of 1 to 000 mg per day and vitamin D supplementation of at least 400 IU per day are recommended concurrently unless hypercalcemia exists [1].

Step 3: Find a Prescriber in New Hampshire

New Hampshire residents have three realistic pathways to a Prolia prescription.

In-Person Endocrinologist or Rheumatologist

Dartmouth Health's endocrinology department, Concord Orthopaedics, and several rheumatology practices across Manchester and Nashua routinely manage osteoporosis with denosumab. New patient wait times at NH endocrinology offices have stretched to 8 to 16 weeks in 2024 due to workforce shortages, according to internal scheduling data reviewed by the HealthRX medical team.

Primary Care Physician or NP in NH

Nurse practitioners in New Hampshire hold full independent practice authority under RSA 326-B, meaning no physician co-signature is required [6]. A primary care NP who is comfortable managing metabolic bone disease can prescribe Prolia independently. Many NH family medicine practices now offer osteoporosis management as a chronic disease service.

Telehealth

New Hampshire law permits telehealth prescribing for established treatment relationships, and the NH Board of Medicine confirmed in 2023 that prescribing for chronic conditions via synchronous video visit satisfies the "appropriate medical evaluation" standard. HealthRX clinicians licensed in NH can review your DXA, labs, and medical history via video, write the Prolia prescription, and coordinate injection delivery with a local NH clinician or infusion center.

The HealthRX NH Prolia Access Framework works as follows. First, a patient completes an online intake with DXA results and medical history. Second, a HealthRX-licensed NH clinician conducts a synchronous video visit, typically within 3 to 5 business days. Third, the clinician orders labs if not already current (within 90 days). Fourth, once labs clear, the prescription is sent to an in-network specialty pharmacy or to the patient's preferred NH injection site. The full cycle from intake to first injection averages 10 to 14 days when labs are already available, and 18 to 24 days when new labs are needed.

Step 4: Navigating Prior Authorization in New Hampshire

Prior authorization (PA) is required by virtually every NH commercial insurer and by Medicare Part B for Prolia administered in a physician office. Anthem BCBS NH, Harvard Pilgrim Health Care (a major NH plan), Ambetter NH, and Medicare Advantage plans operated by Tufts Health and WellSenior all list denosumab as a PA-required specialty medication as of 2025.

A complete PA package for NH insurers typically requires:

1. DXA report with T-score values and scan date (within 24 months for most plans)
2. Diagnosis code M81.0 (age-related osteoporosis without fracture) or M80.xx (with fracture)
3. Documentation of either (a) trial and failure of or contraindication to an oral bisphosphonate (most commonly alendronate 70 mg weekly for at least 6 months) or (b) renal impairment precluding bisphosphonate use (eGFR <35 mL/min)
4. Current calcium and vitamin D supplementation documented in the chart
5. Prescriber letter of medical necessity

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "For patients who are unable to use oral bisphosphonates, denosumab represents an appropriate first-line alternative with strong fracture risk reduction data" [7]. Including that guideline reference in the PA letter strengthens the clinical argument significantly.

Appeal rates for initial PA denials run approximately 18 to 22% in NH based on specialty pharmacy reports, but approval rates on first appeal exceed 70% when a complete package is submitted. The HealthRX clinical team prepares PA documentation as part of the standard workflow for NH patients.

Step 5: How Prolia Is Dispensed and Administered in New Hampshire

Prolia is not a drug patients pick up at a retail pharmacy and administer at home. The 60 mg/mL prefilled syringe requires subcutaneous injection by a trained clinician, making the dispensing pathway different from most oral medications.

Medical office administration (buy-and-bill). Most NH endocrinologists and rheumatologists purchase Prolia directly from a specialty distributor under the buy-and-bill model. The office stocks the drug, administers it, and bills the patient's medical insurance (Medicare Part B or commercial medical benefit, not pharmacy benefit). This is the most common path for established NH specialist patients.

Specialty pharmacy to injection site. For telehealth-initiated prescriptions, a specialty pharmacy ships Prolia (cold-chain, 2 to 8 degrees Celsius) to a participating NH injection site: a primary care office, urgent care center, or home health agency. The patient schedules a brief visit for the injection only. CVS Specialty and Biologics by McKesson both serve NH ZIP codes and can coordinate cold-chain delivery within 3 to 7 business days of PA approval.

503A compounding pharmacies. New Hampshire licenses 503A compounding pharmacies, and at least three NH-licensed 503As are currently registered. However, denosumab is a biologic manufactured via recombinant DNA technology, and FDA guidance strongly discourages compounding of approved biologics when the brand product is commercially available [8]. Prescribing clinicians should discuss this with patients and explain that compounded denosumab carries uncertain bioequivalence. HealthRX does not recommend compounded denosumab when Prolia is commercially accessible.

Step 6: Dosing Schedule and What Happens If You Miss a Dose

The approved dose is 60 mg subcutaneous injection every 6 months. No dose adjustment exists for age, body weight, or renal function. Prolia must be injected in the upper arm, upper thigh, or abdomen.

Missed doses carry a specific clinical risk that is not present with bisphosphonates. Denosumab's anti-resorptive effect reverses rapidly after the 6-month window passes. A study in the Journal of Bone and Mineral Research (N=1,001 FREEDOM extension participants) showed that bone mineral density returned to near-baseline levels within 12 months of stopping denosumab, and vertebral fracture rates rebounded significantly [9]. The Endocrine Society recommends transitioning patients to a bisphosphonate when discontinuing denosumab to prevent this rebound [7].

Practically, this means NH patients should schedule their 6-month injection appointment before leaving the office after each dose. If a dose is delayed by less than 7 months, the injection should be given as soon as possible and the schedule reset. Delays beyond 7 months may require re-evaluation of calcium and vitamin D status before re-dosing.

Insurance Coverage and Cost in New Hampshire

Medicare Part B. Prolia administered in a physician office is covered under Medicare Part B (medical benefit, not Part D) when medical necessity is documented. After the 2025 Part B deductible of $240, patients typically owe 20% coinsurance, which amounts to roughly $300 to $400 per injection at current AWP pricing, unless a Medigap plan covers the coinsurance.

Commercial insurance. Anthem BCBS NH and Harvard Pilgrim typically cover Prolia under the medical benefit with PA. Patient cost-sharing varies by plan design; copays range from $30 to $150 per injection for most mid-tier NH commercial plans after PA approval.

NH Medicaid (NH Healthy Families / Wellcare NH). New Hampshire Medicaid does not cover denosumab for the osteoporosis indication as of January 2025. Patients on Medicaid should ask their prescriber whether alendronate, risedronate, or zoledronic acid (all Medicaid-covered in NH) are clinically appropriate alternatives.

Amgen patient assistance. Amgen's Prolia SupportPlus program (1-800-772-6436) provides free drug to commercially uninsured or underinsured patients with household income at or below 500% of the federal poverty level [10]. NH prescribers and HealthRX coordinators can submit enrollment paperwork on the patient's behalf.

Transferring an Existing Prolia Prescription to New Hampshire

Patients relocating to NH from another state do not need to restart the PA process from scratch if they can provide documentation from their prior prescriber. What you need:

• A copy of your most recent DXA report
• A letter or chart note from the prior prescriber documenting diagnosis, date of last injection, and prior PA approval history
• Lab results from the past 90 days (calcium, vitamin D, creatinine)

An NH-licensed prescriber must still write a new prescription under their DEA and NH license. Telehealth prescribers at HealthRX can accept transferred records digitally and issue the new NH prescription after a video review, typically within one business day of receiving complete records. The specialty pharmacy will require a new prescription regardless of what existed in the prior state.

Special Populations in New Hampshire

Men with osteoporosis. Prolia is FDA-approved for men with osteoporosis at high risk of fracture and for men receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. NH urology and oncology practices managing prostate cancer patients on ADT should consider bone health monitoring every 12 months with DXA and Prolia where indicated.

Glucocorticoid-induced osteoporosis. Patients taking 7.5 mg or more of prednisone equivalent daily for 6 or more months qualify for a separate Prolia indication. The 2017 ACR guideline on glucocorticoid-induced osteoporosis states that denosumab is an appropriate option for high-risk patients who cannot tolerate oral bisphosphonates [11]. NH rheumatology and pulmonology practices managing long-term steroid users should screen annually.

Dental health. Osteonecrosis of the jaw (ONJ) is a rare but serious risk. The incidence in the FREEDOM trial was 0.04% over 36 months in the denosumab arm [2]. NH prescribers routinely recommend a dental examination and completion of any invasive dental procedures before the first injection and avoidance of tooth extractions during treatment where possible.